JP Morgan Chase
CBAY

JP Morgan Chase’s Cymabay Therapeutics CBAY Stock Holding History

JP Morgan Chase’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-85,500
Closed -$2.02M – 8028
2023
Q4 		$2.02M Sell
85,500
-114,800
-57% -$2.04M ﹤0.01% 3828
2023
Q3 		$2.99M Buy
+200,300
New +$2.66M ﹤0.01% 3235
2021
Q2 		– Sell
-200
Closed -$1K – 6689
2021
Q1 		$1K Buy
+200
New +$1.08K ﹤0.01% 6001

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's CBAY Position: Q1 2024 in Review

JP Morgan Chase sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 159,857 shares — an estimated $3.78M sold.

JP Morgan Chase first reported a position in CBAY in Q2 2015 and held it in 26 quarters. The position peaked at $5.41M in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • JP Morgan Chase reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 159,857 Cymabay Therapeutics shares in Q1 2024, an estimated $3.78M.
  • JP Morgan Chase first reported a position in Cymabay Therapeutics in Q2 2015 and held it in 26 quarters.
  • JP Morgan Chase's Cymabay Therapeutics position peaked at $5.41M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.